European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - carcinoma, renal cell - protein kinase inhibitors - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

beacon pharmaceuticals plc - axitinib - tablet - 1 mg

Kenya - English - Pharmacy and Poisons Board

axitinib - tablet - axitinib inn 5mg - axitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - axitinib 3 mg - film-coated tablet - axitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - axitinib 5 mg - film-coated tablet - axitinib

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - axitinib 7 mg - film-coated tablet - axitinib

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - axitinib -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - axitinib - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - axitinib - tablet - 3mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 5mg;   - film coated tablet - 5 mg - active: axitinib 5mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.